Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TransMedics Group ( (TMDX) ) has provided an announcement.
On October 3, 2025, TransMedics, Inc., a subsidiary of TransMedics Group, acquired a fixed-wing aircraft from Teaghlach Aviation, LLC for approximately $14.5 million. This acquisition is part of a series of transactions to build a fleet of 22 aircraft, aimed at enhancing the company’s capabilities in transporting donor organs for its National OCS Program.
The most recent analyst rating on (TMDX) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on TransMedics Group stock, see the TMDX Stock Forecast page.
Spark’s Take on TMDX Stock
According to Spark, TipRanks’ AI Analyst, TMDX is a Outperform.
TransMedics Group’s overall stock score is driven by strong financial performance and positive earnings call highlights, including robust revenue growth and strategic initiatives. However, high valuation metrics and neutral technical indicators slightly temper the outlook. The absence of a dividend yield and high P/E ratio suggest caution, but the company’s growth potential remains promising.
To see Spark’s full report on TMDX stock, click here.
More about TransMedics Group
TransMedics Group is a company operating in the medical industry, focusing on the transportation of donor organs. The company provides services under its National OCS Program, utilizing a fleet of aircraft for organ transport.
Average Trading Volume: 1,070,602
Technical Sentiment Signal: Buy
Current Market Cap: $3.94B
See more data about TMDX stock on TipRanks’ Stock Analysis page.